Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE)

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Due to the delay in the study shceduled, due to the start of competitive study and the approval of Durvalumab from the Ministry of Food and Drug Safety, it was judged that it was difficult to enroll subjects.

Conditions

Stage III NSCLC

Interventions

DRUG: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001
DRUG: PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001

Sponsor

Yonsei University